Analysis

Mid-day market update: Crude oil rises 4%, Fennec Pharmaceuticals shares slide

Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11.

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 49,099,590 cases with around 799,410 deaths. India confirmed a total of at least 34,580,830 cases and 468,790 deaths, while Brazil reported over 22,080,900 COVID-19 cases with 614,310 deaths. In total, there were at least 261,877,540 cases of COVID-19 worldwide with more than 5,219,770 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Information technology shares gained by 1.8% on Monday. Meanwhile, top gainers in the sector included Matterport, Inc MTTR +16.87% (Get Free Alerts for MTTR), up 13% and Arqit Quantum Inc. ARQQ +6.21% (Get Free Alerts for ARQQ) up 10%.

In trading on Monday, financials shares fell 0.1%.

Top Headline

Li Auto Inc. LI +7.5% reported better-than-expected third-quarter financial results.

Li Auto reported third-quarter diluted earnings per ADS of 5 cents, which beat the estimate of a loss of 2 cents, and sales results of $1.21 billion, which beat the $1.16 billion estimate.

The company also reported deliveries of Li ONEs were 25,116 vehicles in the third quarter of 2021, representing a 190% year-over-year increase.

Equities Trading UP

Krystal Biotech, Inc. KRYS +116.58% shares shot up 123% to $88.75 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).

Shares of Adagio Therapeutics, Inc. ADGI +69.03% got a boost, shooting 67% to $41.95 after the company said its COVID-19 monoclonal antibody, ADG20, is likely to retain activity against Omicron, as observed in in vitro models with all other variants of concern identified previously. Morgan Stanley upgraded Adagio Therapeutics from Equal-Weight to Overweight and announced a $49 price target.

NRx Pharmaceuticals, Inc. NRXP +22.44% shares were also up, gaining 29% to $8.72 after the company announced positive data from its ZYESAMI study.

Equities Trading DOWN

Fennec Pharmaceuticals Inc. FENC -48.86% shares tumbled 51% to $4.74 after the company said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark. The FDA indicated that, following a recent inspection of the manufacturing facility of the drug product manufacturer, deficiencies have been identified.

Shares of Allied Healthcare Products, Inc. AHPI -21.88% were down 20% to $6.64 after jumping around 55% on Friday.

Vaxxinity, Inc. VAXX -22.1% was down, falling 21% to $14.53. Vaxxinity, earlier during the month, priced its IPO at $13 per share.

Commodities

In commodity news, oil traded up 4% to $70.87, while gold traded up 0.1% to $1,786.20.

Silver traded down 0.8% Monday to $22.93 while copper rose 0.9% to $4.3285.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 gained 0.66%, the Spanish Ibex Index rose 0.62% and the German DAX 30 gained 0.01%. Meanwhile, the London’s FTSE 100 rose 1.02%, French CAC 40 gained 0.43% and Italy’s FTSE MIB climbed 0.63%.

Spain's annual inflation rate increased to 5.6% in November from 5.4% in the prior month. Producer prices in Italy jumped 20.4% year-over-year in October. Consumer credit in the UK rose by GBP 0.706 billion in October, while number of mortgage approvals for house purchase declined to 67.2 thousand in October.

Economics

The pending home sales index surged 7.5% for October, versus analysts’ expectations for a 0.9% growth.

The Dallas Fed manufacturing index dropped slightly to 11.8 in November from a three-month high level of 14.6 in October.

Federal Reserve Bank of New York President John Williams will speak at 3:00 p.m. ET.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.


RELATED CONTENT

Loading ...



Copyright © 2024 FOREXSTREET S.L., All rights reserved.